Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics Methods: This retrospective cohort study analyzed pre-3V and post-3V...
Main Authors: | Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, James L. Weese |
---|---|
Format: | Article |
Language: | English |
Published: |
Advocate Aurora Health
2022-07-01
|
Series: | Journal of Patient-Centered Research and Reviews |
Subjects: | |
Online Access: | https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1952&context=jpcrr |
Similar Items
-
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
by: Elisa Bossi, et al.
Published: (2022-11-01) -
Carbamazepine and Hematological Malignancies
by: İrfan Yavaşoğlu, et al.
Published: (2013-12-01) -
Infections in children and adolescents with hematological malignancies
by: Andishe Attarbaschi, et al.
Published: (2023-12-01) -
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
by: Carolin Krekeler, et al.
Published: (2022-11-01) -
The Research Advances of Aptamers in Hematologic Malignancies
by: Yongkang Liao, et al.
Published: (2023-01-01)